RT Journal Article
SR Electronic
T1 The SENTINEL study of differentiated service delivery models for HIV treatment in Malawi, South Africa, and Zambia: research protocol for a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.22.23290361
DO 10.1101/2023.05.22.23290361
A1 Pascoe, Sophie
A1 Huber, Amy
A1 Mokhele, Idah
A1 Lekodeba, Nkgomeleng
A1 Ntjikelane, Vinolia
A1 Sande, Linda
A1 Tcherini, Timothy
A1 Haimbe, Prudence
A1 Rosen, Sydney
A1 the AMBIT SENTINEL study team
YR 2023
UL http://medrxiv.org/content/early/2023/05/23/2023.05.22.23290361.abstract
AB Background Many countries in sub-Saharan Africa are rapidly scaling up “differentiated service delivery” (DSD) models for HIV treatment to improve the quality of care, increase access, reduce costs, and support the continued expansion and sustainability of antiretroviral therapy (ART) programs. Although there is some published evidence about the health outcomes of patients in DSD models, little is known about their impacts on healthcare providers’ job satisfaction, patients’ quality of life, costs to providers or patients, or how DSD models affect resource allocation at the facility level.Methods SENTINEL is a multi-year observational study that will collect detailed data about DSD models for ART delivery and related services from 12 healthcare facilities in Malawi, 24 in South Africa, and 12 in Zambia. The first round of SENTINEL included a patient survey, provider survey, provider time-and-motion observations, and facility resource use inventory. A survey of clients testing for HIV and a supplement to the facility resource use component to describe service delivery integration will be added for the second round. The patient survey will ask up to 10 patients enrolled in each DSD model at each study site about their experiences in HIV care and in DSD models, costs incurred seeking treatment, and preferences for HIV service delivery. The provider survey will ask up to 10 providers per site about the impact of DSD models on their positions and clinics. The time-and-motion component will directly observe the time use of a sample of providers implementing DSD models. Finally, the resource utilization component will collect facility-level data about DSD model availability and enrollment and the human and other resources needed to implement them. SENTINEL is planned to include four or more approximately annual rounds of data collection between 2021 and 2026.Discussion As national DSD programs for HIV treatment mature, it is important to understand how individual healthcare facilities are interpreting and implementing national guidelines and how healthcare workers and clients are adapting to new models of service delivery. SENTINEL will help policy makers and program managers understand the benefits and costs of differentiated service delivery and improve resource allocation going forward.Competing Interest StatementThe authors declare that they have no competing interests. Several individuals in the AMBIT SENTINEL study team hold positions in a government agency that has supervisory authority over some of the healthcare facilities involved in this study.Funding StatementFunding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to Boston University. The funders had no role in study design, data collection, analysis, or interpretation of data or in the writing of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SENTINEL study was approved with a separate protocol for each study country by the Boston University Institutional Review Board (Malawi H-41345, March 8, 2021; South Africa H-41402, March 11, 2021; Zambia H-41512, April 20, 2021) and by the University of the Witwatersrand Human Research Ethics Committee (Malawi M210270, June 9, 2021; South Africa M210241 June 4, 2021; Zambia M210342, September 30, 2021). In addition, the protocol for Malawi was approved by the Malawi National Health Science Research Committee (21/03/2672, March 12, 2021). The protocol for South Africa was approved by Provincial Health Research Committees through the National Health Research Database for each study district. The protocol for Zambia was approved by the ERES-Converge IRB (2021-Mar-012, April 7, 2021), the Zambia National Health Research Authority (NHRA00001/23/04/2021, April 23, 2021) and the Zambia Ministry of Health (MH/105/25/3, May 3, 2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe present work is a protocol paper and does not contain any data.ACadherence clubARTantiretroviral therapyCAGcommunity adherence groupDSDdifferentiated service deliveryEx-pupexternal pickup pointFac-pupfacility pickup pointFTfast trackMMDmulti-month dispensingMIPmother-infant pairs model